Health Care · Pharmaceuticals

Alkermes plc ALKS

$51.32-1.41 (-2.67%)delayed quote · as of 2026-07-28 15:20 UTC

Open ALKS in the workspaceCharts, statements, and the evidence behind every figure — free to start.

Market cap

$8.6B

Previous close

$52.73

Volume

1.0M

52-week range

$25.17 – $55.67

Verdictconfidence 96% · high

Solid footing across most dimensions.

5 of 5 dimensions score well.

Value603/5 checks

Growth804/5 checks

Quality804/5 checks

Health1004/4 checks

Momentum1005/5 checks

Fair-value estimate $134.64 per share (2-stage FCF · individual beta · 10Y Rf 4.7%) — the price sits 62% below it.

Every check behind these scores — with its numbers, source, and evidence link — is in the workspace. Free account required.

Key ratioslatest filing FY 2025

Value

P/E TTM

57.0

P/E FWD

31.3

EV/EBITDA TTM

35.3

PEG

1.63

FCF yield TTM

2.6%

Growth

Revenue 3y

+9.9%/yr

Revenue YoY

−5.2%

Expected EPS

+82.0%

Quality

Piotroski F

6 / 9

ROIC

ALAN GLOBAL INTELLIGENCE · alanglobalintelligence.comquote as of 2026-07-28 15:20 UTC · fundamentals FY 2025 · SEC EDGAR

Verdict

Reading ALKS’s filed statements…

Continue with ALKS in ALAN

Full evidence trail, financial statements back a decade, valuation history, charts, and alerts.

Open in the workspace Create free account

For information and research only. Not investment advice. ALAN does not place trades or execute orders. Figures come from the sources shown and can lag the market; verify independently before making decisions. Past performance is not predictive of future results.